Certain of CareFusion’s Alaris infusion systems, a product line already affected by recalls, are the subject of another warning over potential air bubbles that may be transferred to the patient. CareFusion (NYSE:CFN) issued a new warning over potential issues with its Alaris infusion pumps, a product line already targeted by 2 recalls. The San Diego-based device maker warned clinics that its Alaris GP Infusion pumps produce air bubbles that are too small to trigger the device’s detection and alarm system, creating a possibility that an air bubble may be transferred to a patient, which could then result in a pulmonary air embolism. CareFusion discovered the issue through post-market surveillance of the Alaris systems, according to the warning, which was also noted by Hong Kong regulators.
